QCG
GILD icon

Quadrant Capital Group’s Gilead Sciences GILD Stock Holding History

Quadrant Capital Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.13M Buy
36,809
+3,157
+9% +$442K 0.15% 93
2025
Q4 		$4.13M Buy
33,652
+250
+0.7% +$30.4K 0.12% 117
2025
Q3 		$3.71M Sell
33,402
-1,015
-3% -$115K 0.12% 124
2025
Q2 		$3.82M Buy
34,417
+7,384
+27% +$786K 0.14% 116
2025
Q1 		$3.03M Buy
27,033
+15,608
+137% +$1.61M 0.11% 119
2024
Q4 		$1.06M Sell
11,425
-476
-4% -$42.9K 0.07% 181
2024
Q3 		$998K Buy
11,901
+491
+4% +$37.5K 0.07% 202
2024
Q2 		$783K Sell
11,410
-1,153
-9% -$76.9K 0.06% 234
2024
Q1 		$920K Sell
12,563
-1,142
-8% -$87.8K 0.07% 198
2023
Q4 		$1.11M Buy
13,705
+276
+2% +$21.5K 0.1% 158
2023
Q3 		$1.01M Sell
13,429
-29
-0.2% -$2.23K 0.1% 146
2023
Q2 		$1.04M Buy
13,458
+257
+2% +$20.5K 0.1% 139
2023
Q1 		$1.1M Sell
13,201
-295
-2% -$24.4K 0.11% 126
2022
Q4 		$1.16M Buy
13,496
+2,424
+22% +$192K 0.13% 113
2022
Q3 		$683K Buy
11,072
+951
+9% +$60K 0.09% 150
2022
Q2 		$626K Buy
10,121
+1,672
+20% +$104K 0.08% 169
2022
Q1 		$502K Buy
8,449
+247
+3% +$15.8K 0.06% 224
2021
Q4 		$596K Buy
8,202
+69
+0.8% +$4.75K 0.07% 184
2021
Q3 		$568K Buy
8,133
+374
+5% +$26.3K 0.08% 176
2021
Q2 		$534K Sell
7,759
-7,433
-49% -$496K 0.08% 177
2021
Q1 		$982K Buy
15,192
+8,301
+120% +$535K 0.16% 97
2020
Q4 		$401K Buy
6,891
+207
+3% +$12.5K 0.07% 182
2020
Q3 		$422K Sell
6,684
-2,458
-27% -$170K 0.09% 146
2020
Q2 		$703K Sell
9,142
-6,010
-40% -$461K 0.16% 105
2020
Q1 		$1.13M Buy
15,152
+5,959
+65% +$412K 0.19% 94
2019
Q4 		$577K Buy
9,193
+410
+5% +$26.7K 0.07% 249
2019
Q3 		$542K Sell
8,783
-2,126
-19% -$139K 0.08% 216
2019
Q2 		$720K Buy
10,909
+967
+10% +$63.6K 0.11% 145
2019
Q1 		$629K Buy
9,942
+3,129
+46% +$208K 0.11% 151
2018
Q4 		$418K Sell
6,813
-215
-3% -$15K 0.11% 148
2018
Q3 		$531K Buy
7,028
+258
+4% +$19.5K 0.15% 104
2018
Q2 		$460K Sell
6,770
-394
-5% -$27.8K 0.16% 113
2018
Q1 		$528K Buy
7,164
+334
+5% +$26.6K 0.19% 95
2017
Q4 		$476K Sell
6,830
-131
-2% -$9.95K 0.19% 102
2017
Q3 		$551K Buy
6,961
+430
+7% +$32.9K 0.23% 89
2017
Q2 		$439K Buy
6,531
+410
+7% +$27.3K 0.19% 99
2017
Q1 		$409K Sell
6,121
-179
-3% -$12.6K 0.18% 104
2016
Q4 		$441K Buy
6,300
+471
+8% +$35K 0.22% 83
2016
Q3 		$453K Sell
5,829
-520
-8% -$42.2K 0.3% 62
2016
Q2 		$520K Buy
6,349
+65
+1% +$5.77K 0.36% 56
2016
Q1 		$570K Buy
6,284
+123
+2% +$11.1K 0.37% 48
2015
Q4 		$617K Buy
6,161
+454
+8% +$47.2K 0.43% 43
2015
Q3 		$555K Buy
5,707
+14
+0.2% +$1.55K 0.38% 46
2015
Q2 		$662K Buy
+5,693
New +$622K 0.42% 43

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Quadrant Capital Group's GILD Position: Q1 2026 in Review

Quadrant Capital Group increased its Gilead Sciences (GILD) stake by 9.4% in Q1 2026, buying an estimated $442K and bringing the position to 36,809 shares worth $5.13M. The position accounts for 0.15% of the portfolio, ranked #93.

Quadrant Capital Group first reported a position in GILD in Q2 2015 and has held it in 44 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Quadrant Capital Group held 36,809 shares of Gilead Sciences worth $5.13M as of Q1 2026.
  • Quadrant Capital Group bought 3,157 Gilead Sciences shares in Q1 2026, an estimated $442K.
  • Gilead Sciences made up 0.15% of Quadrant Capital Group's portfolio in Q1 2026, its #93 holding.
  • Quadrant Capital Group first reported a position in Gilead Sciences in Q2 2015 and has held it in 44 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.